Release of substance P during peritoneal dialysis: effects of intervention. Controlled cross-over study of the neurokinin-1 receptor antagonist Aprepitant

niversity of Gothenburg0 个研究点目标入组 32 人开始时间: 2012年11月9日最近更新: 2020年6月2日

适应症

试验速览

暂无简介。

•Included persons are treated with PD since at least 3 months and are males aged 20-90 or post-menopausal females up to age 90.
•Included persons must have positive ultrafiltration (ultrafiltration volume larger than 0 ml/24 hours measured not more than one month earlier).
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 16
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 16

•Moderate to serious liver damage, potential or known damage to the blood-brain barrier (e.g. brain tumor, meningitis, encephalitis), peritonitis during the last two months and treatment with any of the following drugs: warfarin, corticosteroider, pimozid, terfenadin, astemizol, cisaprid, ciklosporin, takrolimus, sirolimus, everolimus, alfentanil, diergotamin, ergotamin, fentanyl, kinidin, rifampicin, fenytoin, karbamazepin, fenobarbital och metotrexat.

发起方

niversity of Gothenburg